Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-21
2007-08-21
Shameem, Golam (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S541000
Reexamination Certificate
active
11342270
ABSTRACT:
Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.
REFERENCES:
patent: 2954380 (1960-09-01), Shapiro et al.
patent: 3218328 (1965-11-01), Shapiro et al.
patent: 4145435 (1979-03-01), Szmuszkovicz
patent: 4179501 (1979-12-01), Szmuszkovicz
patent: 4598087 (1986-07-01), Horwell
patent: 4656182 (1987-04-01), Horwell
patent: 4663343 (1987-05-01), Horwell et al.
patent: 4855316 (1989-08-01), Horwell et al.
patent: 4880800 (1989-11-01), Wallis
patent: 4906655 (1990-03-01), Horwell et al.
patent: 5019588 (1991-05-01), Horwell et al.
patent: 5051428 (1991-09-01), Horwell et al.
patent: 5059620 (1991-10-01), Stout et al.
patent: 5492825 (1996-02-01), Jan et al.
patent: 5506257 (1996-04-01), MacLeod et al.
patent: 5637583 (1997-06-01), MacLeod et al.
patent: 5670335 (1997-09-01), Jan et al.
patent: 5728535 (1998-03-01), Lester et al.
patent: 5734021 (1998-03-01), Lester et al.
patent: 5750537 (1998-05-01), Nomura et al.
patent: 5817698 (1998-10-01), Brown et al.
patent: 5885984 (1999-03-01), MacLeod et al.
patent: 6174879 (2001-01-01), MacLeod et al.
patent: 6180632 (2001-01-01), Myers et al.
patent: 6210809 (2001-04-01), Okutomi et al.
patent: 6214810 (2001-04-01), Fermini et al.
patent: 6451819 (2002-09-01), Alanine et al.
patent: 6521619 (2003-02-01), Link et al.
patent: 6649603 (2003-11-01), Lum
patent: 2005/0026993 (2005-02-01), Beatch et al.
patent: 2005/0038256 (2005-02-01), Barrett et al.
patent: 2005/0070552 (2005-03-01), Fedida et al.
patent: 2005/0119315 (2005-06-01), Fedida et al.
patent: 2005/0209307 (2005-09-01), Bain et al.
patent: 1234808 (1988-04-01), None
patent: 1235122 (1988-04-01), None
patent: 2004575 (1990-06-01), None
patent: 2058502 (1993-06-01), None
patent: 2172513 (1995-03-01), None
patent: 2244209 (1997-07-01), None
patent: 2008391 (1997-12-01), None
patent: 2289055 (1999-01-01), None
patent: 2268590 (2000-10-01), None
patent: 2132841 (2001-03-01), None
patent: 2 259 260 (1974-06-01), None
patent: 2 658 401 (1978-07-01), None
patent: 3 517 901 (1985-12-01), None
patent: 147085 (1985-07-01), None
patent: 147085 (1985-07-01), None
patent: 222533 (1987-05-01), None
patent: 372466 (1990-06-01), None
patent: 372466 (1990-06-01), None
patent: 380063 (1990-08-01), None
patent: 380063 (1990-08-01), None
patent: 552386 (1993-07-01), None
patent: 720605 (2001-12-01), None
patent: 215963 (1998-02-01), None
patent: 02-270864 (1990-11-01), None
patent: WO93/19056 (1993-09-01), None
patent: WO94/07843 (1994-04-01), None
patent: WO94/14435 (1994-07-01), None
patent: WO95/08544 (1995-03-01), None
patent: WO95/28155 (1995-10-01), None
patent: WO96/18615 (1996-06-01), None
patent: WO96/23894 (1996-08-01), None
patent: WO97/32857 (1997-09-01), None
patent: WO97/49680 (1997-12-01), None
patent: WO99/02159 (1999-01-01), None
patent: WO99/03468 (1999-01-01), None
patent: WO99/11252 (1999-03-01), None
patent: WO99/16431 (1999-04-01), None
patent: WO99/50205 (1999-10-01), None
patent: WO99/50225 (1999-10-01), None
patent: WO 00/47547 (2000-08-01), None
patent: WO 00/51981 (2000-09-01), None
patent: WO 01/96335 (2001-12-01), None
patent: WO 03/105756 (2003-12-01), None
patent: WO 2004/008103 (2004-01-01), None
patent: WO 2004/098525 (2004-11-01), None
patent: WO 2004/099137 (2004-11-01), None
Stevenson et al, Dec. 2, 2004, N. Engl. J. Med, 351; 23, 2437-2440.
Alzheimer's Disease Information Page [online], [retrieved on Oct. 3, 2006]. Retrieved from the Internet, URL; <http://www.ninds.nih.gov/disorders/alzheimersdisease/alzheimersdisease.htm>.
Adcock, J.J. et al., (2003) “RSD931, a novel anti-tussive agent acting on airway sensory nerves” Br J Pharm, 138:407-416.
Allen I. Bain et al., “Ion Channel Modulating Compounds and Uses Thereof,” U.S. Appl. No. 09/283,873, filed Mar. 31, 1999, now abandoned.
Allen I. Bain et al., “Ion Channel Modulating Compounds and Uses Thereof,” U.S. Appl. No. 09/680,988, filed Oct. 6, 1999, now abandoned.
Altria, Kevin D. et al., (2001) “Capillary Electrophoresis as a Routine Analytical Tool in Pharmaceutical Analysis” LCGC 19(9):972-985.
Amin et al., (1996) “RPR 101821, a New Potent Cholesterol-lowering Agent: Inhibition of Squalene Synthase and 7-Dehydrocholesterol Reductase”, Naunyn-Schmiedeberg's Arch Pharmacol 353:233-240.
Bain et al., (1997) “Better Antiarrhythmics? Development of Antiarrhythmic Drugs Selective for Ischaemia-Dependent Arrhythmias”, Drug Development Research 42:198-210.
Barret, T. D. et al., (1996) “Glibenclamide Possesses Transient, Ischaemia Selective Class III Antiarrhythmic Actions But does not Prevent Ischaemic Arrhythmias” BPS Proceedings 116P.
Barrett, T. D. et al., (1997) “A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits” J Pharmacol Toxicol Methods, 37:27-36.
Barrett, T. D. (2000) “Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats” Eur J Pharm, 398:365-374.
Barrett, T.D. et al., (1996) “Atypical Dose Response curves for Antiarrhythmic Drugs” BPS Proceedings 115P.
Barrett, Terrance D. (1997) “Ischemia Selective Electrophysiological and antiarrhythmic actions of RSD1019 in ischemic cardiac tissue” J Mol Cell Cardiol, pp. 197.
Barrett, Terrance D. et al., (2000) “RSD 1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits” Br J Pharm, 131.405-414.
Beatch et al., (2002) “RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodelled Atria”, Pharmacologist, 44(2) (Supplement I), A15: XIVthWorld Congress of Pharmacology: Meeting Abstracts.
Beatch et al., (2002) “Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electricially Remodeled Atria”, (NASPE) North Amer. Soc. of Pacing & Electrophysiol. 24:698 (Abstract 702).
Beatch, G. et al., “Effect of a Novel Anti-tussive Compound CP1 Against Citric Acid Induced Cough in Guinea-Pigs”Proc West Pharmacol Soc, 2001.
Beatch, G. et al., Electrophysiological Profile of RSD1235, A New Drug for Conversion of Atrial Fibrillation.
Beatch, G. et al., “RSD1235 Rapidly and Effectively Terminates Atrial Fibrillation” Abstract submission ESC Congress Aug. 30-Sep. 3, 2003, in Vienna, Austria.
Beatch, G. N. et al., “RSD1235, A Novel Atrial-Selective Antiarrhythmic Drug, Shows Rapid and Extensive Oral Absorption in Man” 12thInternational Congress on Cardiovascular Pharmacotherapy, May, 7-10, 2003, Barcelona, Spain.
Beatch, G. N. et al., (2002) “Ventricular Fibrillation, and Uncontrolled Arrhythmia Seeking New Targets” Drug Develop Res 55: 45-52.
Beatch, G.N. et al., (1996) “Antihistamine-induced Ventricular Arrhythmias” BPS Proceedings 120P.
Beatch, G.N. et al., (1997) “Characterization of a Non-Human Primate Model of Drug-Induced Torsades De Pointes” Proc. West. Pharmacol. Soc., 40: 13-16.
Beatch, G.N. et al., (2002) “RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria” PACE 24 (Part II):698. Abstract 702.
Bian et al., (1998) “Effects of K-opioid receptor stimulation in the heart and the involvement of protein kinase C” Brit. J. Pharmacol. 124:600-606.
Billman, (2003) “RSD-1235”, Current Opinion Investigational Drugs 4(3):352-354.
Boiadjiev et al., (1996) “pH-Sensitive Exciton Chirality Chromophore . . . Solvatochromic Effects on Circular Dichroism Spectra”, Tetrahedron: Asymmetry 7(10):2825-2832.
Bowen et al., (1992)“Characterization of the enantiomers of cis-n-[2-
Beatch Gregory N
Plouvier Bertrand M C
Sheng Tao
Walker Michael J A
Wall Richard A
Cardiome Pharma Corp.
Cheng Karen
Seed IP Law Group PLLC
Shameem Golam
LandOfFree
Ion channel modulating compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ion channel modulating compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ion channel modulating compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3868299